From LSD to magic mushrooms, psychedelic drugs are being explored as a way to help treat mental health conditions.
Could psychedelics be the next cannabis?
Several recent occurrences, which in many ways parallel the early days of cannabis, suggest the often stigmatized drug category could be poised for growth.
In March, the FDA approved Johnson & Johnson’s Spravato, a nasally administered form of ketamine, for treatment-resistant depression.
Around a month later, Imperial College London announced the formation of the world’s first psychedelic-dedicated research center, followed in September by the launch of a similar center in the US by Johns Hopkins University.